Effect of cessation of zidovudine prophylaxis to reduce vertical transmission on maternal HIV disease progression and survival

Journal of Acquired Immune Deficiency Syndromes

Volumn 32, Issue 2, 2003, Pages 170-181

  Bardeguez, Arlene D ^a,n   Shapiro, David E ^b   Mofenson, Lynne M ^c   Coombs, Robert ^d   Frenkel, Lisa M ^d   Fowler, Mary Glenn ^e   Huang, Sharon ^b   Sperling, Rhoda S ^f,g   Cunningham, Bethann ^h   Gandia, Jorge ⁱ   Maupin, Robert ^j   Zorrilla, Carmen D ^k   Jones, Theodore ^l   O'Sullivan, Mary Jo ^m  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^g MERCK RESEARCH LABORATORIES   (United States)

^h FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

ⁱ San Juan City Hospital   (Puerto Rico)

^j LOUISIANA STATE UNIV HLTH SCI C   (United States)

^k UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

^l WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

ⁿ RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

more..

Author keywords

Antiretroviral therapy; Disease progression; Genotypic resistance; PACTG 076 protocol; Perinatal transmission; Women; ZDV chemoprophylaxis

Indexed keywords

ANTIRETROVIRUS AGENT; PLACEBO; VIRUS RNA; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; FEMALE; FOLLOW UP; GENETIC RESISTANCE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; INFECTION PREVENTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MATERNAL DISEASE; MULTICENTER STUDY; NONHUMAN; PERINATAL MORBIDITY; PRIORITY JOURNAL; PUERPERIUM; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SURVIVAL; T LYMPHOCYTE; TREATMENT WITHDRAWAL; VERTICAL TRANSMISSION;

EID: 0037321530     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200302010-00009     Document Type: Article

References (28)

1. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994;331:1173-80.
2. Stiehm RE, Lambert JS, Mofenson LM, et al. Efficacy of zidovudine and human immunodeficiency virus hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: results of Pediatric AIDS Clinical Trials Group protocol 185. J Infect Dis 1999;179:567-75.
3. Cooper ER, Charurat M, Burns DN, et al. for the Women and Infants Transmission Study: Trends in antiretroviral therapy and mother-infant transmission of HIV. J Acquir Immune Defic Syndr 2000;24:45-7.
4. Centers for Disease Control and Prevention. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. MMWR 1998;(RR-2):1-30. Updated January 24, 2001 (updated guidelines can be accessed at: http://www.hivatis.org).
5. Centers for Disease Control and Prevention. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. MMWR 1998;47(RR-5):39-83. Updated April 23, 2001 (updated guidelines can be accessed at: http://ww.hivatis.org).
6. Sperling RS, Shapiro DE, McSherry GD et al. Safety of the maternal-infant zidovudine regimen used in the Pediatric AIDS Clinical Trial Group 076 Study. AIDS 1998;12:1805-13.
7. Culnane M, Fowler MG, Lee SS, et al. Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. JAMA 1999;281:151-7.
8. de Jong MD, de Boer RJ, de Wolf F, et al. Overshoot of HIV-1 viremia after early discontinuation of antiretroviral treatment. AIDS 1997;11(Suppl):F79-84.
9. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992; 41:1-19.
10. Calvelli T, Denny TN, Paxton H, et al. Guideline for flow cytometric immunophenotyping: a report from the National Institute of Allergy and Infectious Diseases, Division of AIDS. Cytometry 1993;14:702-15.
11. ACTG virology manual for HIV laboratories. 3rd ed. Publication number NIH-94-3828. Bethesda, MD: Division of AIDS, National Institutes of Allergy and Infectious Diseases, NIH, 1994.
12. Lin HJ, Myers LE, Yen-Lieberman B, et al. Multicenter evaluation of methods for the quantitation of plasma HIV-1 RNA. J Infect Dis 1994;170:553-62.
13. Brambilla R, Leung S, Lew J, et al. Absolute copy number and relative change in determinations of human immunodeficiency virus type 1 RNA in plasma: effect of an external standard on kit comparisons. J Clin Microbiol 1998;36:311-4.
14. Mulder J, Resnick R, Saget B, et al. A rapid and simple method for extracting human immunodeficiency virus type 1 RNA from plasma: enhanced sensitivity. J Clin Microbiol 1997;35:1278-80.
15. Sperling RS, Shapiro DE, Coombs RW, et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infants. N Engl J Med 1996;335:1621-9.
16. Frenkel LM, Wagner LE, Atwood SM, et al. Specific, sensitive and rapid assay for human immunodeficiency virus type 1 pol mutations associated with resistance to zidovudine and didanosine. J Clin Microbiol 1995;33:342-7.
17. Edelstein RE, Nickerson DA, Tobe VO, et al. An oligonucleotide ligation assay (OLA) detecting mutations in the HIV-1 pol gene associated with resistance to zidovudine, didanosine and lamivudine. J Clin Microbiol 1998;36:569-72.
18. Eastman PS, Shapiro DE, Combs RW, et al. Maternal viral genotypic zidovudine resistance and infrequent failure of zidovudine therapy to prevent perinatal transmission of human immunodeficiency virus type 1 in Pediatric AIDS Clinical Trials Group Protocol 076. J Infect Dis 1998;177:557-64.18.
19. Amato DA. The design and analysis of equivalence trials. In Finkelstein DM, Schoenfeld DA, eds. AIDS clinical trials: guidelines for design and analysis. New York: Wiley-Liss, 1995: 155-76.
20. Cox DR, Oakes D. Analysis of survival data. London: Chapman and Hall, 1984.
21. Wei LJ, Johnson WE. Combining dependent test with incomplete repeated measurements. Biometrika 1985;72:359-64.
22. Gehan EA. A generalized two-sample Wilcoxon test for doubly censored data. Biometrika 1965;52:650-3.
23. Burns DN, Landesman S, Minkoff H, et al. The influence of pregnancy on human immunodeficiency virus type 1 infection: antepartum and postpartum changes in human immunodeficiency virus type 1 viral load. Am J Obstet Gynecol 1998;178:355-9.
24. Cao Y, Krogstad P, Korber BT, et al. Maternal HIV-1 viral load and vertical transmission of infection: the Ariel Project for the prevention of HIV transmission from mother to infant. Nat Med 1997;3:549-52.
25. Welles SL, Pitt J, Colgrove R, et al. HIV-1 genotypic zidovudine drug resistance and the risk of maternal-infant transmission in the Women and Infants Transmission Study. AIDS 2000;14:263-71.
26. Kully C, Yerly S, Kind C, et al. Codon 215 mutations in human immunodeficiency virus-infected pregnant women. J Infect Dis 1999;179:705-8.
27. Boucher CAB, Tersmette M, Lange JMA, et al. Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy. Lancet 1990;336:585-90.
28. Richman DD, Grimes JM, Lagakos SW. Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus. J Acquir Immune Defic Syndr Hum Retrovirol 1990;3:743-6.